Category: Vaccine

Page 135«..1020..134135136137..140150..»

Diphtheria Outbreak Ongoing in Guinea Precision Vaccinations News – Precision Vaccinations

December 10, 2023

(Precision Vaccinations News)

The U.S. Centers for Disease Control and Prevention (CDC) continues to publish Trave Health Notices regardingdiphtheria outbreaks in various countries in 2023.

On December 7, 2023, the CDC posted aLevel 2 - Practice Enhanced Precautions notice regardingan outbreak of diphtheria in several districts in Guinea, which is located in western Africa.

Diphtheriais a severe infection caused by strains ofCorynebacterium diphtheriaebacteria that make a toxin. The toxin can cause people to get very sick. Diphtheria bacteria spread from person to person through respiratory droplets, like from coughing or sneezing.

People can also get sick from touching open sores or ulcers of people ill with diphtheria, according to the CDC.

Diphtheria is a vaccine-preventable disease.

Unfortunately, an estimated 16% of children worldwide hadno or incomplete vaccination coverage.

The U.S. CDC saysmost travelers visiting outbreak areas should receive an age-appropriate dose of diphtheria toxoid-containing vaccineif they are not fully vaccinatedor have not received a booster dose within five years before departure.

There are 11 vaccines available for use to help protect against diphtheria in 2023. Diphtheria and other travel vaccinesare offered at manyclinics and pharmacies in the U.S.

See more here:

Diphtheria Outbreak Ongoing in Guinea Precision Vaccinations News - Precision Vaccinations

J&J to emphasize cancer drugs, stop much of its vaccine research – STAT

December 10, 2023

Eight months into his tenure, Johnson & Johnsons R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the companys research and development efforts. Fierce Biotech previously reported J&J is cutting vaccine R&D.

Get unlimited access to award-winning journalism and exclusive events.

Originally posted here:

J&J to emphasize cancer drugs, stop much of its vaccine research - STAT

Quick takes: Test-to-treat extension, PAHO dengue alert, thin-film vaccine development – University of Minnesota Twin Cities

December 10, 2023

A systematic review and meta-analysis estimates a nearly 50% long-COVID rate months after infection in Africa, with psychiatric conditions the most common manifestations.

Published today in Scientific Reports, the February 2023 literature search and analysis involved 25 observational, English language long-COVID studies with 29,213 infected African patients.

Nearly half (48%) of the studies were from Egypt, the average patient age was 42years (range, 7 to 73 years), 59.3% were females, and the median follow-up was 3 months.

"In low-income countries, the estimates of its [long COVID's] incidence vary greatly due to a significant number of hidden infections (i.e., asymptomatic or undisclosed) and difficulties in accessing testing," the study authors wrote.

The team, led by researchers from the University of Bari in Italy, found a long-COVID rate of 48.6%, with a predominance of psychiatric conditions, especially post-traumatic stress disorder (25.8%).

The most common neurologic symptom was cognitive impairment (15%), and shortness of breath was the most common respiratory symptom (18.3%), followed by cough (10.7%). Other notable symptoms were loss of appetite (12.7%), weight loss (10.4%), fatigue (35.4%), and muscle pain (15.5%). A quarter (25.4%) of patients reported poor quality of life.

The high incidence of fatigue is particularly worrisome because of its debilitating nature. "This is concerning because, in Africa, it has the potential to lead to important impairment in productivity and further loss of economic agency," the researchers wrote.

The study recommends identifying at-risk people and defining treatment strategies and recommendations for African long-COVID patients.

Likewise, the mental illness burden in long-COVID patients poses a challenge on a continent with few mental health resources: "These findings highlight the pressing need for immediate policy implementation and reallocation of resources to address this severely underestimated public health issue."

Risk factors for long COVID included older age and hospitalization during infection.

"The study recommends identifying at-risk people and defining treatment strategies and recommendations for African long-COVID patients," the authors concluded, noting that high-quality studies are urgently needed.

Here is the original post:

Quick takes: Test-to-treat extension, PAHO dengue alert, thin-film vaccine development - University of Minnesota Twin Cities

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine – PR Newswire

December 10, 2023

Antigen-specific T cell responses were observed at all dose levels

IFN and IL-17, immune-mediated biomarkers of T cell activation, increased over time from baseline

Vaccine was safe and well tolerated

Conference call to commence today at 6:30 p.m. ET

SAN JOSE, Calif., Dec. 6, 2023 /PRNewswire/ --Anixa Biosciences, Inc.("Anixa"orthe "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced new and updated positive results from the Phase 1 clinical trial of its breast cancer vaccine. The trial is being conducted in collaboration with Cleveland Clinic with funding by a grant from the U.S. Department of Defense.

The data were presented at the 2023 San Antonio Breast Cancer Symposium by G. Thomas Budd, M.D., staff physician at Cleveland Clinic Cancer Institute and principal investigator of the study, in a poster entitled "Phase I Trial of alpha-lactalbumin vaccine in high-risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC."

Patients who had been curatively treated for TNBC received three vaccinations given once every two weeks. IFN and IL-17, which are T cell immune response indicators (cellular immunity), and antibody production (B cell humoral immunity) were measured to evaluate the vaccination effect. Data from the 16 patients treated to date showed that:

Anixa and Cleveland Clinic plan to investigate additional intermediate dose levels and continue studying the vaccine's safety and immunologic effects in two additional patient cohorts.

"The data from our Phase 1 trial to date has exceeded our expectations, and we are pleased with our progress. This vaccine is designed to direct the immune system to destroy TNBC cancer cells through a mechanism that has never previously been utilized for cancer vaccine development," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "We look forward to reviewing additional data as the trial continues to completion, and we are in the planning stages of the Phase 2/3 studies of this vaccine. Our goal is to initially evaluate the vaccine's ability to prevent recurrence of cancer in survivors, and continue with extension studies to eventually determine its effectiveness in preventing the initial onset of TNBC."

"There is a large unmet need for preventing TNBC, an aggressive form of breast cancer with few targeted treatment options available," said Dr. Budd, Cleveland Clinic. "We are encouraged by the data gathered to date and look forward to determining the optimal vaccine dose in additional patient cohorts. Our hope is that future studies will demonstrate that the antigen-specific T cell responses we observed translate to the prevention of breast cancer recurrence."

Anixa is the exclusive worldwide licensee to the novel breast cancer vaccine technology invented at Cleveland Clinic, the site of the Phase 1 trial. The grant from the U.S. Department of Defense was made directly to Cleveland Clinic.

Conference Call Information

Anixa is pleased to invite all interested parties to participate in a conference call, during which this new data will be discussed.

Conference Call Details:

Presentation host:

Anixa management, with special guest speakers

Date and time:

Today, December 6, 2023, at 6:30 p.m. ET

Phone access:

Registration Link to receive your dial-in number and unique PIN

Webcast:

Available at http://www.anixa.com under "Events & Presentations"

About Triple-Negative Breast CancerOne in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.

About Anixa Bioscience's Breast Cancer VaccineAnixa's breast cancer vaccine takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, -lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express -lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing. This vaccine technology was invented by the late Dr. Vincent Tuohy, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research in the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. Dr. Tuohy was inventor of the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences. He was entitled to a portion of the commercialization revenues received by Cleveland Clinic and also held equity in Anixa.

AboutAnixa Biosciences,Inc.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR- T, known as chimeric endocrine receptor T-cell (CER-T) technology. The Company's vaccine portfolio includes a novel vaccine being developed in collaboration with Cleveland Clinic to preventbreastcancerspecificallytriple negativebreastcancer (TNBC),themostlethalform of the disease as well as a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. Anixa's unique business model of partnering with world-renowned research institutions on clinical development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit http://www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebookand YouTube.

Forward-Looking Statements: Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10- Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward- looking statements when evaluating the information presented in this press release.

Contacts:Stephen KilmerInvestor Relations [emailprotected] 646-274-3580

Mike Catelani President,COO&CFO [emailprotected] 408-708-9808

SOURCE Anixa Biosciences, Inc.

Read more here:

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine - PR Newswire

GOP Presidential Hopefuls Use Trumps Covid Record to Court … – KFF Health News

November 29, 2023

Former President Donald Trump often seems proud to advertise his administrations record on speedily developing covid-19 vaccines.

On the campaign trail to win another term in the White House, though, he also has knocked the use of those very vaccines. In October, for example, he unleashed a barrage of social media attacks on Ron DeSantis pandemic record by reposting claims that the Florida governor who is running against him in the Republican presidential primaries was too active in vaccinating Sunshine State residents.

In a further twist, Trump simultaneously circulated an MSNBC article suggesting DeSantis wasnt vaccinating his constituents enough.

Trumps tap dance touting Operation Warp Speeds success at developing vaccines while criticizing vaccine use is emblematic of how pandemic politics are intensifying broader vaccine politics. Republican presidential candidates currently trailing the former president in polls are contorting their messaging to court the partys vaccine-skeptical voters. No one embraces, without qualification, the utility of a public health measure that has saved millions of lives.

Like Trump, even the more establishment candidates cant seem to avoid embracing the anti-vaccine leanings of the partys base. Take Nikki Haley, who formerly served as governor of South Carolina and ambassador to the United Nations and has been rising in the polls. In the waning days of the Trump administration, she was pro-vaccine. But by the end of November 2021, in an interview with the Christian Broadcasting Network, she repeated dubious anti-vaccine claims: for instance, that the vaccine could undermine a womans fertility. (Studies consistently show no effect.)

The GOP has gained the allegiance of a minority of people who feel very strongly about the safety of vaccines, Robert Blendon, a Harvard professor of public health, told KFF Health News. Presidential candidates are trying to use this sensibility as a cultural issue to signal distrust in scientists, other experts, and government authority in general, he said.

The resulting dynamic carries the risk of reaching beyond the current election cycle to affect public health policy in years to come, leading to lower rates among schoolchildren and seniors of vaccinations that protect them from measles, shingles, and HPV. Even as candidates try to weaponize this rhetoric, theyve had little luck in changing the former presidents front-runner status.

A recent KFF survey of adults about their plans to get vaccinated against the flu, respiratory syncytial virus, known as RSV, and covid found that partisanship remains a key predictor of how people view vaccines. Confidence in the safety of the updated covid vaccines split sharply along party lines, with more than 8 in 10 Democrats saying they trust the new shots, compared with 1 in 3 Republicans.

But unease about covid or the vaccines is not Republican primary voters top issue Blendon said concerns around the border, crime, and inflation are and its not clear vaccine-focused attacks hurt Trump.

I didnt like his response to covid, says an Iowa business owner featured in a critical ad from a well-funded political action committee that questioned Trumps handling of the pandemic. I thought he probably got led a little bit by the bureaucrats, he says, hitting Trump on his bragging about the development of the vaccine and contrasting Trump unfavorably with certain governors the man in the ad thought performed better against covid. (Images of DeSantis, otherwise unnamed, flash by.)

The result? The ad produced a backlash and, when audience-tested with focus groups, improved the former presidents support, according to a memo summarizing the political action committees attempts to dent the front-runner.

Candidates nonetheless are trying to make hay, acknowledged Joe Grogan, who led the Domestic Policy Council during the Trump administration. But I think people have a lot of other targets for ire about the pandemic.

Trump is not at the top of the list for Republican primary voters, Grogan said. Hes not on Page 2. Or 3, or 4. It begins with the media, the public health bureaucracy, or Big Tech companies.

Voters have strong, yet divided and sometimes inconsistent, opinions. Some, like Joshua Sharff, 48, of Chesapeake, Virginia, are opposed to the covid vaccines and to candidates who support the shots as safe and effective. Sharff describes himself as a conservative voter who intends to support the Republican nominee for president. Though hes vaccinated, he said, If youre a governor or a president and you tell me that I have to take a vaccine that has not been tried, that has not been tested, and ignores the science, thats a problem for me. Youre taking away my freedoms as an American citizen.

These positions have led Sharff away from Trump and toward DeSantis, who has promoted anti-vaccine and anti-public health positions in his quest for the nomination.

Trump pushed the vaccine very hard and recently came out, when he began to get pushback on it, that it was somebody elses fault, Sharff said. Thats not true.

Other Republican voters said the vaccine is not key to their vote.

It will not sway my vote one way or another, said Kimberly Hunt, 59, of Melville, Tennessee.

In chasing these voters, some candidates are distancing themselves from initial, pro-vaccine positions to embrace outspoken views against the shot. Vivek Ramaswamy, a biotech entrepreneur, started out as a vaccine cheerleader. But then he flipped, coming out against vaccine mandates and saying this summer that he regretted getting vaccinated. (His wife, a doctor, said she had no regrets.)

The most vocal of all is DeSantis.

Appearing on the right-leaning PBD Podcast on Oct. 30, DeSantis attacked Trump and the corrupt medical swamp in D.C. for overselling a vaccine that, despite the initial federal guidance, could not prevent infection or transmission of covid. The Centers for Disease Control and Prevention recommends the vaccine for anyone 6 months and older to protect against serious illness.

Though he initially encouraged people to get vaccinated in early 2021, DeSantis pivoted months later, banning vaccine passports for businesses and government entities, and later approving legislation prohibiting vaccine mandates in the state. That fall, he also appointed a new Florida surgeon general, physician Joseph Ladapo, whose guidance on covid vaccines contradicts CDC recommendations. DeSantis formed a Public Health Integrity Committee to assess, and generally dispute, federal health recommendations.

When the CDC released new vaccine guidance in September, Florida responded with its own advisory casting doubt on the safety of the boosters.

This anti-vaccine positioning hasnt helped DeSantis. He has been losing support nationally and is generally polling third behind Haley and Trump in New Hampshire, a key early primary state. He headlined a medical freedom town hall in Manchester on Nov. 1 with Ladapo as a special guest.

Among the candidates remaining, DeSantis may be the most famous convert to the politics of anti-vaccination, but, with this subject, Haley has more experience.

In the 2021 CBN interview, she said mandates are not what America does. But the forceful declaration is merely the end of an ambivalent record, and, for critics, demonstrates her willingness to get in sync with the demands of the GOP base. As a state legislator, she supported 2007 legislation that included a mandate for HPV vaccines before voting against it; and later, as governor, she vetoed an effort to promote those vaccinations.

Bakari Sellers now a commentator on CNN, but at the time a lawmaker who spearheaded that bill told KFF Health News, Thats the biggest Nikki Haley issue that there is: She kind of has her finger in the air.

The issue of vaccines may affect the general election: Even as Trump defends his vaccine record, its nevertheless clear he has support from the anti-vaccine crowd. An analysis by Politico, for example, found overlap among donors to independent presidential candidate Robert F. Kennedy Jr., who is staunchly opposed to vaccines, and Trump.

The willingness among politicians to assail whats traditionally looked on as a foundational achievement of public health is likely to lead to turbulence for doctors themselves. Allison Ferris, a primary care physician and an associate professor at Florida Atlantic University, said people should be listening to their doctors and not to presidential candidates about whether to take the new covid vaccines. But that message is hard to deliver in the current climate.

It is a tricky position to be in, said Ferris, who co-authored recently released guidance advising doctors to counsel patients that frequent covid vaccination will likely become a necessity.

See the article here:

GOP Presidential Hopefuls Use Trumps Covid Record to Court ... - KFF Health News

Get paid to get a COVID vaccine: Coastal Health District offers new incentive – WJCL News Savannah

November 29, 2023

The Coastal Health District is holding various vaccination incentive events throughout the month of December to encourage residents to get the updated COVID-19 vaccine. Everyone age 6 months and older who has not already received the updated COVID vaccine is eligible.The updated COVID vaccines by Pfizer and Moderna were released in September of this year. The Coastal Health District says the vaccines provide protection against COVID variants that are currently circulating. CHD said receiving an updated COVID vaccination significantly reduces your risk of severe complications and hospitalization from COVID infection.In Chatham County, vaccine incentive events will be held Dec. 12 and 14 at the clinic at 1395 Eisenhower Drive and are by appointment only. Anyone with an appointment who is vaccinated at one of the events will receive a $100 Walmart gift card. The Chatham County Health Department offers the COVID vaccine by Pfizer.To make an appointment for the events in Chatham County, visit https://coastalhealthdistrict.as.me/incentive-event to schedule online or call the health department at 912-356-2441.In Bryan County, a vaccine incentive event will be held by appointment only on Dec. 14 from 8:30 11:30 a.m. at both Bryan County Health Department locations. Anyone with an appointment who is vaccinated at the event will receive a $100 Walmart gift card. The Bryan County Health Department offers the COVID vaccine by Moderna. To make an appointment for the Bryan County event, call the Richmond Hill clinic at 912-756-2611 or the Pembroke clinic at 912-653-4333 during clinic hours.In Effingham County, the vaccine incentive event is by appointment only and will be held Dec. 5 at the clinic at 802 Hwy 119 South in Springfield. Anyone with an appointment who is vaccinated at the event will receive a $100 Walmart gift card. The Effingham County Health Department offers the COVID vaccine by Moderna.To make an appointment for the event in Effingham County, visit https://coastalhealthdistrict.as.me/effingham-incentiveday to schedule online or call the health department at 912-754-6484 during clinic hours.In Liberty County, the vaccine incentive event is by appointment only and will be held Dec. 8 from 8 a.m. 1 p.m. at the clinic at 1113 East Oglethorpe Highway in Hinesville. Anyone with an appointment who is vaccinated at the event will receive a $100 retail gift card. The Liberty County Health Department offers the COVID vaccine by Moderna.To make an appointment for the event in Liberty County, visit https://coastalhealthdistrict.as.me/liberty-incentiveday to schedule online or call the health department at 912-876-2173 during clinic hours.In Long County, the vaccine incentive event is by appointment only and will be held Dec. 21 from 8 a.m. 11:30 a.m. and 1 p.m. - 5:30 p.m. at the clinic at 584 North Macon St. in Ludowici. Anyone with an appointment who is vaccinated at the event will receive a $100 retail gift card. The Long County Health Department offers the COVID vaccine by Moderna.To make an appointment for the event in Long County, visit https://coastalhealthdistrict.as.me/long-incentiveday to schedule online or call the health department at 912-545-2107 during clinic hours.In McIntosh County, the vaccine incentive event is by appointment only and will be held Dec. 14 from 1 p.m. - 6 p.m. at the clinic at 1335 Georgia Hwy 57 in Townsend. Anyone with an appointment who is vaccinated at the event will receive a $100 retail gift card. The McIntosh County Health Department offers the COVID vaccine by Moderna.To make an appointment for the event in McIntosh County, visit https://coastalhealthdistrict.as.me/mcintosh-incentiveday to schedule online or call the health department at 912-832-5473.The cost of COVID vaccination is covered by many insurance plans at no cost to the patient. For individuals without health insurance coverage, a federal program will cover the cost of vaccination. For a full list of vaccination incentive events, visit coastalhealthdistrict.org/incentive.

The Coastal Health District is holding various vaccination incentive events throughout the month of December to encourage residents to get the updated COVID-19 vaccine.

Everyone age 6 months and older who has not already received the updated COVID vaccine is eligible.

The updated COVID vaccines by Pfizer and Moderna were released in September of this year. The Coastal Health District says the vaccines provide protection against COVID variants that are currently circulating. CHD said receiving an updated COVID vaccination significantly reduces your risk of severe complications and hospitalization from COVID infection.

In Chatham County, vaccine incentive events will be held Dec. 12 and 14 at the clinic at 1395 Eisenhower Drive and are by appointment only. Anyone with an appointment who is vaccinated at one of the events will receive a $100 Walmart gift card. The Chatham County Health Department offers the COVID vaccine by Pfizer.

To make an appointment for the events in Chatham County, visit https://coastalhealthdistrict.as.me/incentive-event to schedule online or call the health department at 912-356-2441.

In Bryan County, a vaccine incentive event will be held by appointment only on Dec. 14 from 8:30 11:30 a.m. at both Bryan County Health Department locations. Anyone with an appointment who is vaccinated at the event will receive a $100 Walmart gift card. The Bryan County Health Department offers the COVID vaccine by Moderna.

To make an appointment for the Bryan County event, call the Richmond Hill clinic at 912-756-2611 or the Pembroke clinic at 912-653-4333 during clinic hours.

In Effingham County, the vaccine incentive event is by appointment only and will be held Dec. 5 at the clinic at 802 Hwy 119 South in Springfield. Anyone with an appointment who is vaccinated at the event will receive a $100 Walmart gift card. The Effingham County Health Department offers the COVID vaccine by Moderna.

To make an appointment for the event in Effingham County, visit https://coastalhealthdistrict.as.me/effingham-incentiveday to schedule online or call the health department at 912-754-6484 during clinic hours.

In Liberty County, the vaccine incentive event is by appointment only and will be held Dec. 8 from 8 a.m. 1 p.m. at the clinic at 1113 East Oglethorpe Highway in Hinesville. Anyone with an appointment who is vaccinated at the event will receive a $100 retail gift card. The Liberty County Health Department offers the COVID vaccine by Moderna.

To make an appointment for the event in Liberty County, visit https://coastalhealthdistrict.as.me/liberty-incentiveday to schedule online or call the health department at 912-876-2173 during clinic hours.

In Long County, the vaccine incentive event is by appointment only and will be held Dec. 21 from 8 a.m. 11:30 a.m. and 1 p.m. - 5:30 p.m. at the clinic at 584 North Macon St. in Ludowici. Anyone with an appointment who is vaccinated at the event will receive a $100 retail gift card. The Long County Health Department offers the COVID vaccine by Moderna.

To make an appointment for the event in Long County, visit https://coastalhealthdistrict.as.me/long-incentiveday to schedule online or call the health department at 912-545-2107 during clinic hours.

In McIntosh County, the vaccine incentive event is by appointment only and will be held Dec. 14 from 1 p.m. - 6 p.m. at the clinic at 1335 Georgia Hwy 57 in Townsend. Anyone with an appointment who is vaccinated at the event will receive a $100 retail gift card. The McIntosh County Health Department offers the COVID vaccine by Moderna.

To make an appointment for the event in McIntosh County, visit https://coastalhealthdistrict.as.me/mcintosh-incentiveday to schedule online or call the health department at 912-832-5473.

The cost of COVID vaccination is covered by many insurance plans at no cost to the patient. For individuals without health insurance coverage, a federal program will cover the cost of vaccination.

For a full list of vaccination incentive events, visit coastalhealthdistrict.org/incentive.

Read more here:

Get paid to get a COVID vaccine: Coastal Health District offers new incentive - WJCL News Savannah

Grant Aims to Strengthen Vaccine Production in Africa – Pharmacy Times

November 29, 2023

The recent announcement of a US$40 million grant from the Bill & Melinda Gates Foundation to support production of new messenger ribonucleic acid (mRNA) vaccines in Africa presents opportunities to boost clinical trials and strengthen a potential foundation of the continents health care landscape. AnmRNA vaccine uses a copy of a molecule called messengerRNA(mRNA) to produce an immune response.1

Image credit: Media Lens King | stock.adobe.com

Closing the Gap in Vaccine Equity

Africa has long grappled with concerns over clinical trials, particularly in the context of vaccine development. The perception that Africans are exploited as subjects in drug testing has persisted, despite the fact that less than 3% of global clinical trials take place in Africa.2 This underrepresentation is largely due to a lack of capacity, infrastructure and access for such trials. With a rapidly growing population of almost 1.5 billion people, opportunities abound.

Clinical trials are essential for modern medicine, allowing scientists to rigorously assess the safety and efficacy of pharmaceutical products.3 The global clinical trials market is valued at over $48.2 billion in 2023 and expected to grow to $73.2 billion within the next 5 years.4 The vast majority of trials are conducted in Western countries.

The $40 million grant Bill & Melinda Gates Foundation to support mRNA vaccine development will contribute to addressing these issues, with a primary focus on improving vaccine equity in Africa.5 This commitment acknowledges the need for Africa to take an active role in vaccine development, production, and distribution, thus ensuring timely access to life-saving vaccines.

A Catalyst for Health Care Innovation

The grant allocates $5 million each to Institut Pasteur in Dakar and Biovac in South Africa, which will employ an mRNA research and manufacturing platform developed by Belgium-based Quantoom Biosciences.5 An additional $20 million will be provided to Quantoom to further advance the technology and lower costs and the remaining $10 million is earmarked for companies yet to be named.5

Unlike previous COVID-19 mRNA vaccines that received expedited emergency approval, future vaccines developed in Africa are likely to follow a more extended timeline of 3 to 7 years. This approach aims to ensure the safety and effectiveness of vaccines tailored to the health care needs of the African population.

By investing in an ecosystem for pharmaceutical research and vaccine production, the grant sets the stage to strengthen back and forward linkages for Africa to address future health care challenges with increased self-reliance.

Empowering Local Vaccine Production

Africa has long relied on foreign sources for vaccines, often experiencing delays and difficulties in accessing immunizations.6 The grant signifies a shift toward local vaccine production and a reduction in dependence on external sources. This transition aligns with the African Union's Pharmaceutical Manufacturing Plan for Africa, which seeks to promote domestic pharmaceutical production.7

Promoting Collaborations

The grant also provides a bridge for collaborations between African institutions and global health care leaders. These partnerships can facilitate knowledge exchange, technology transfer, and capacity building. Established institutions such as the London School of Hygiene and Tropical Medicine, the Pasteur Institute, and the University of California, San Francisco, have already developed productive collaborations with African counterparts. The Bill & Melinda Gates Foundation's grant is poised to strengthen connections of this nature and create a network of healthcare experts working together to improve healthcare in Africa.

Visionary Future for African Health Care

The Bill & Melinda Gates Foundation's $40 million grant is a substantial step forward for African health care. It underscores a commitment to vaccine equity, health care innovation, and self-reliance. The grant offers Africa an opportunity to strengthen vaccine development and production, fostering an ecosystem for health care innovations that meet local needs.

Investments of this nature can prove transformative and represent more than just financial supportthey provide beacons of hope for a healthier Africa. By strengthening the continent's health care infrastructure, promoting local vaccine production, and facilitating global collaborations, the grant represents an important milestone toward better health care for all Africans.

References

1. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol. 2012;9(11):1319-1330. doi:10.4161/rna.22269

2. FHI Clinical. Increasing Clinical Research in Africa Presents An Opportunity to Address Global Health Challenges. Accessed November 29, 2023. https://www.fhiclinical.com/increasing-clinical-research-in-africa-presents-an-opportunity-to-address-global-health-challenges/

3. Jager W. The importance of clinical trials in advancing medical research. Annals of Clinical Trials and Vaccines Research. 2023;13(3).

4. Markets and Markets. Clinical Trials Market by Phase (Phase I, II, III), Service Type (Laboratory, Analytical Testing, Patient Recruitment, Protocol Designing), Therapeutic Area (Oncology, Cardiology, Neurology), and Application (Vaccine, mAbs, CGT) Global Forecast to 2028. September 2023. Accessed November 29, 2023. https://www.marketsandmarkets.com/Market-Reports/clinical-trials-market-405.html?gclid=Cj0KCQjw4bipBhCyARIsAFsieCyely7rdTVx0I35EsURLb3ljVBsoG4tehKqnI5oDmYgCscG9BR8y64aAlaWEALw_wcB

5. Candid. Gates Foundation commits $40 million for mRNA vaccines in Africa. October 14, 2023. Accessed November 29, 2023. https://philanthropynewsdigest.org/news/gates-foundation-commits-40-million-for-mrna-vaccines-in-africa

6. Sidib M. Vaccine inequity: Ensuring Africa is not left out. Brookings. January 24, 2022. Accessed November 29, 2023. https://www.brookings.edu/articles/vaccine-inequity-ensuring-africa-is-not-left-out/

7. Byaruhanga J. The Pharmaceutical Manufacturing Plan for Africa. AUDA-NEPAD. August 24, 2020. Accessed November 29, 2023. https://www.nepad.org/news/pharmaceutical-manufacturing-plan-africa#:~:text=The%20PMPA%20is%20designed%20to,benefits%20through%20sustainability%2C%20competitiveness%2C%20and

About the Author

Christopher Burke is the Managing Director of WMC Africa, a public relations and marketing agency based in Kampala, Uganda. Christopher has a strong background in communications, public health, governance and development with 30 years experience based in Africa and East Asia.

See more here:

Grant Aims to Strengthen Vaccine Production in Africa - Pharmacy Times

Unpacking COVID-19 Vaccine Attitudes: Exploring Hesitancy and … – Cureus

November 29, 2023

Specialty

Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional. Infectious Disease Integrative/Complementary Medicine Internal Medicine Internal Medicine-Pediatrics Medical Education and Simulation Medical Physics Medical Student Nephrology Neurological Surgery Neurology Nuclear Medicine Nutrition Obstetrics and Gynecology Occupational Health Oncology Ophthalmology Optometry Oral Medicine Orthopaedics Osteopathic Medicine Otolaryngology Pain Management Palliative Care Pathology Pediatrics Pediatric Surgery Physical Medicine and Rehabilitation Plastic Surgery Podiatry Preventive Medicine Psychiatry Psychology Pulmonology Radiation Oncology Radiology Rheumatology Substance Use and Addiction Surgery Therapeutics Trauma Urology Miscellaneous

Read more here:

Unpacking COVID-19 Vaccine Attitudes: Exploring Hesitancy and ... - Cureus

After Cyfendus’ full approval, Emergent clinches $75M anthrax … – FiercePharma

November 29, 2023

Armed with a full FDA approval after four years of supplying its anthrax vaccine under a pre-emergency use authorization, Emergent BioSolutions is expanding its countermeasure supply pact with the United States.

The nations Biomedical Advanced Research and Development Authority (BARDA) is laying out $75 million to exercise an option on an existing deal for additional doses of Emergents two-dose anthrax shot Cyfendus, according to a securities filing.

The FDA signed off on Emergents vaccineformerly known as AV7909in July. Prior to the shots formal green light, Emergent had been furnishing the U.S. Department of Health and Human Services with the product since 2019.

The immunization includes anthrax vaccine absorbed (AVA) and an adjuvant and is administered as two doses over 14 days. Its intended for post-exposure prophylaxis in adults 18 to 65.

Under the newly modified deal, deliveries of Cyfendus are expected to begin this year and wrap up by the end of March 2024, Emergent said. The company did not specify how many doses its supplying to the U.S.

BARDA and Emergent first extended their partnership to develop and manufacture Cyfendus back in 2016. After submitting a pre-emergency use authorization package in December 2018, Emergent delivered the first pre-EUA doses of Cyfendus to the U.S. government in 2019.

For years, supplying medical countermeasures to the government has formed Emergents bread-and-butter business. Aside from its anthrax shot, Emergent produces vaccines for smallpox and Ebola, as well as the popular opioid overdose reversal agent Narcan.

Emergents 4mg Narcan nasal spray, for its part, won a historic over-the-counter approval back in March, teeing up direct-to-consumer sales at places like drug stores, convenience stores, supermarkets and gas stations.

Meanwhile, big changes have been brewing at Emergent this year. In late June, Emergents long-time CEO Robert Kramer stepped down from all his posts, lining up an interim replacement in Haywood Miller, the managing director of Berkely Research Group.

Come August, Emergent announced it was de-emphasizing its CDMO services business to shore up its work on core medical countermeasures and Narcan. In turn, the company unveiled plans to eliminate its chief operating officer and ax hundreds of jobs.

Continued here:

After Cyfendus' full approval, Emergent clinches $75M anthrax ... - FiercePharma

University of Montana receives $12.3M contract for work on TB vaccine – KPAX News

November 29, 2023

MISSOULA A vaccine for tuberculosis exists, but TB is still the 2nd leading infectious killer in the world after COVID-19, according to the World Health Organization.

With a $12.3 million contract from the National Institutes of Health, researchers at the University of Montana are hoping to improve the vaccine for TB and positively influence global health, the Daily Montanan reports.

Last month, the Missoula flagship announced UM and its research partners were awarded a five-year contract to develop a new adjuvant to be used with the TB vaccine.

Adjuvants are substances that boost the effectiveness of vaccines, and UMs Center for Translational Medicine has a couple of decades worth of work on those substances.

This funding represents tremendous support for our continuous research efforts in advancing safe and efficient adjuvants and formulation strategies for further development of vaccine candidates against TB, said Walid Abdelwahab, a co-principal investigator on the project, in a statement. This contract is a strong endorsement of our exceptional vaccine research team at UM.

Earlier this fall, UM announced a separate vaccine project to prevent overdosing on fentanyl and heroin is headed for human trials in early 2024. That work came out of the separate $33.4 million NIH contract inked several years ago.

The most recent contract, for the work on TB, allows the development and clinical evaluation of safe and effective adjuvants to help the threat of infection around the world, said Jay Evans, director of the Center for Translational Medicine and co-principal investigator.

In 2022 alone, the World Health Organization said 1.3 million people died from TB, but tuberculosis is curable and preventable.

TB affects a significant portion of the global population, and the only licensed vaccine, BCG, has limited effectiveness, Evans said. Thus, the development of an effective vaccine is critical to end the global TB epidemic.

The UM research will involve both undergraduate and graduate students, offering them a chance to improve global health, the university said.

There is extraordinary research ongoing at UM that could positively impact the lives of countless people, Evans said.

The project also includes researchers from the University of Chicago, the Texas Biomedical Research Institute, and Missoula-based Inimmune Corp., a corporate development partner of UM.

Inimmune is a biotech company located at the universitys business incubator, MonTEC. UM said it will assist with vaccine manufacturing efforts and advancement of this new technology to human clinical trials.

Daily Montanan is part of States Newsroom, a network of news bureaus supported by grants and a coalition of donors as a 501c(3) public charity. Daily Montanan maintains editorial independence. Contact Editor Darrell Ehrlick for questions: info@dailymontanan.com. Follow Daily Montanan on Facebook and Twitter.

The rest is here:

University of Montana receives $12.3M contract for work on TB vaccine - KPAX News

Page 135«..1020..134135136137..140150..»